Two companies that have spent decades trying to develop cell therapies for diabetes are set to merge, with the aim of working together to take on a market also being pursued by Vertex and CRISPR ...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.